Nebraska football defeats Wisconsin 44-25, securing program’s first bowl game since 2016
Angel Reese is one of the most popular athletes in sports and with that notoriety comes its share of hardships. However, with the advancement of technology, the issues Reese faces are different than those of past greats. The WNBA star opened up about her experiences navigating the growth of AI and the breeding ground for fake news. Reese took to her Unapologetically Angel Podcast to share her thoughts on AI. Her longtime manager, Jeanine Ogbonnaya, joined in the conversation to shed light on the difficulties of a female athlete concerning AI. Reese pointed out how easily people believe fake news and AI, even using a relative as an example. She said, Reese isn’t a stranger to criticism. However, the use of AI to tarnish her brand is in a completely different ballpark. One of the biggest fake news stories surrounding Reese insinuated that the Chicago Sky star received a lifetime ban from the WNBA. The fake reports suggested that Reese was using illegal PEDs. Reese didn’t have trouble debunking that narrative. Moreover, she revealed the worst experience consisted of an interaction involving her uncle. The 6-foot-3 forward recalled an instance when her uncle sent her obscene AI-generated pictures of herself under the assumption it was real. Both Reese and Jeanine display their disgust but can recognize this is, unfortunately, a problem that will stay. “We tried to take down everything, but you literally can’t,” Jeanine said. “There’s freedom of speech.” The WNBA did not ban Angel Reese In October, a viral claim made the rounds on the internet stating the WNBA had banned Angel Reese for the use of steroids. The source of these claims came from YouTube and Facebook posts, which people quickly proved to be fraudulent . These claims failed to provide any evidence nor did the WNBA make a statement addressing the situation. They alluded that Reese’s absences for the remainder of the season were due to her punishment from the league. In reality, it was due to a wrist injury. Additionally, the source, a YouTube channel titled ‘Basket Hoops’ were die-hard Caitlin Clark fans. Therefore, it is safe to assume they meant for the video to serve as propaganda against Reese, a rival of Clark. These rumors are fake and there is no truth whatsoever. Reese will suit up in the inaugural season of the Unrivaled League, and then return to the WNBA for her sophomore season.THE MOJ: Lengthy list of coaching candidates as new Lions regime vows toughnessMoscow and Washington maintain a strategic protocol to alert each other about intercontinental ballistic missile launches, as stated by Sergei Karakayev, commander of the Russian Strategic Missile Forces, reported on Monday by Russian news agencies. According to Karakayev, the Russian Federation provides the United States with a 24-hour notice prior to any planned launch of intercontinental ballistic missiles and submarine-launched ballistic missiles. This communication aims to foster transparency between the two powers. Similarly, the United States ensures reciprocal notification, which includes specifics such as the intended launch date, location, and designated warhead impact area, to maintain mutual understanding and minimize misunderstandings. (With inputs from agencies.)
No. 7 Tennessee dispatches UT Martin to remain undefeatedJanet Nguyen to be sworn in as First District county supervisor next week
Neurogene Inc. sees significant stock purchases by Samsara BioCapital
Neurogene Inc. sees significant stock purchases by Samsara BioCapitalCowboys set for Thanksgiving visit from Giants after ending 5-game losing streakNo. 9 SMU aims to improve playoff odds vs. Cal
Financial giants have made a conspicuous bearish move on POET Technologies. Our analysis of options history for POET Technologies POET revealed 54 unusual trades. Delving into the details, we found 9% of traders were bullish, while 74% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $219,512, and 50 were calls, valued at $2,702,382. Projected Price Targets Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $3.0 to $11.0 for POET Technologies during the past quarter. Volume & Open Interest Trends In terms of liquidity and interest, the mean open interest for POET Technologies options trades today is 4353.52 with a total volume of 144,184.00. In the following chart, we are able to follow the development of volume and open interest of call and put options for POET Technologies's big money trades within a strike price range of $3.0 to $11.0 over the last 30 days. POET Technologies Option Volume And Open Interest Over Last 30 Days Significant Options Trades Detected: Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume POET CALL SWEEP BEARISH 04/17/25 $0.9 $0.8 $0.8 $8.00 $160.2K 1.8K 2.3K POET CALL SWEEP BEARISH 01/16/26 $1.75 $1.55 $1.55 $7.00 $155.1K 2.7K 1.3K POET CALL TRADE BULLISH 01/15/27 $1.5 $1.25 $1.5 $10.00 $150.0K 10.1K 2.2K POET CALL SWEEP BEARISH 01/15/27 $1.5 $1.4 $1.4 $10.00 $131.4K 10.1K 4.3K POET CALL SWEEP BEARISH 01/16/26 $1.2 $1.1 $1.1 $10.00 $110.0K 8.2K 1.8K About POET Technologies POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The group's operations are located in Allentown, PA, Shenzhen, China, and Singapore. Having examined the options trading patterns of POET Technologies, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Present Market Standing of POET Technologies Trading volume stands at 10,474,973, with POET's price up by 34.81%, positioned at $7.76. RSI indicators show the stock to be may be overbought. Earnings announcement expected in 78 days. What The Experts Say On POET Technologies 1 market experts have recently issued ratings for this stock, with a consensus target price of $7.0. Unusual Options Activity Detected: Smart Money on the Move Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access .* An analyst from Northland Capital Markets downgraded its action to Outperform with a price target of $7. Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest POET Technologies options trades with real-time alerts from Benzinga Pro . © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
CIBC Asset Management Inc purchased a new stake in Revolution Medicines, Inc. ( NASDAQ:RVMD – Free Report ) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,767 shares of the company’s stock, valued at approximately $216,000. A number of other hedge funds have also modified their holdings of the business. GAMMA Investing LLC raised its position in shares of Revolution Medicines by 55.8% in the third quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock valued at $28,000 after buying an additional 222 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Revolution Medicines during the 3rd quarter worth $93,000. Nisa Investment Advisors LLC boosted its holdings in shares of Revolution Medicines by 10.5% during the second quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock worth $131,000 after purchasing an additional 320 shares during the last quarter. KBC Group NV grew its position in shares of Revolution Medicines by 12.9% in the third quarter. KBC Group NV now owns 3,221 shares of the company’s stock valued at $146,000 after purchasing an additional 368 shares during the period. Finally, Natixis acquired a new position in Revolution Medicines in the first quarter valued at $196,000. 94.34% of the stock is owned by hedge funds and other institutional investors. Wall Street Analyst Weigh In Several analysts have commented on RVMD shares. HC Wainwright lifted their price target on Revolution Medicines from $62.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Wedbush restated an “outperform” rating and issued a $59.00 target price on shares of Revolution Medicines in a report on Thursday, August 8th. Guggenheim increased their price target on shares of Revolution Medicines from $72.00 to $82.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. JPMorgan Chase & Co. boosted their price objective on shares of Revolution Medicines from $54.00 to $63.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Oppenheimer increased their target price on Revolution Medicines from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $61.00. Insider Activity In other news, insider Mark A. Goldsmith sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $44.93, for a total transaction of $449,300.00. Following the completion of the transaction, the insider now directly owns 300,170 shares in the company, valued at approximately $13,486,638.10. This represents a 3.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink . Also, Director Barbara Weber sold 5,200 shares of Revolution Medicines stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $48.02, for a total transaction of $249,704.00. Following the completion of the sale, the director now owns 13,065 shares of the company’s stock, valued at approximately $627,381.30. This trade represents a 28.47 % decrease in their position. The disclosure for this sale can be found here . Insiders sold 127,866 shares of company stock worth $6,355,624 over the last ninety days. Corporate insiders own 8.00% of the company’s stock. Revolution Medicines Stock Performance Revolution Medicines stock opened at $56.75 on Friday. The firm has a market capitalization of $9.55 billion, a PE ratio of -15.81 and a beta of 1.40. Revolution Medicines, Inc. has a one year low of $20.98 and a one year high of $62.40. The stock’s 50 day moving average price is $50.55 and its 200 day moving average price is $44.54. Revolution Medicines ( NASDAQ:RVMD – Get Free Report ) last announced its earnings results on Wednesday, November 6th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.05). During the same quarter last year, the firm posted ($0.99) EPS. On average, analysts forecast that Revolution Medicines, Inc. will post -3.51 earnings per share for the current fiscal year. About Revolution Medicines ( Free Report ) Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Recommended Stories Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. ( NASDAQ:RVMD – Free Report ). Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter .
